Ann: App 4E / Full Year Statutory Accounts, page-41

All six patients have been biopsied, and the Company believes, based on preliminary results reported for three of these patients, that TT-034 has clinical proof of concept for the production of shRNA in the liver from a single administration;

Can I just ask what people think of this. Does this mean in the 6 dosed that only 3 demonstrated proof of concept. Is this only 50% effective at transduction or is it maybe only detectable in 3 cause the dosed were so low?

Sorry having difficulty interpreting.